Dr.Roberto Collazo-Maldonado (@collazor1) header
Dr.Roberto Collazo-Maldonado (@collazor1) profile picture

Love Nephrology and baseball.Partner Dallas Nephrology Associates.This is a personal account. Teaching/practicing/learning Nephrology for living.

Dallas, TX,Comerio,PR
Joined July 2013
Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)Photo by Dr.Roberto Collazo-Maldonado (@collazor1)
Dr.Roberto Collazo-Maldonado retweeted
CELEBRATING EXCELLENCE AT DNA! We are proud to announce that 15 of our physicians have been recognized as D Magazine’s Best Doctors in Dallas County for 2026! Join us in congratulating these remarkable physicians! We are grateful for the difference they make every day!
1
1
44
Dr.Roberto Collazo-Maldonado retweeted
Nephro power 💪🏻💪🏻
The authors analyze the degree to which clinical specialties are shielded from, or threatened by, AI depending on how much of their work requires in-person physical interaction. Learn more: nejm.ai/3UDkrIv
3
6
574
Dr.Roberto Collazo-Maldonado retweeted
Pt with massive proteinuria (20g), AKI, history of IV drug use, chemo/radiation and artificial joint for malignancy, multiple infections. Massive amyloidosis, AA type. #renalpath #pathtwitter #nephrology
2
21
53
1,790
Dr.Roberto Collazo-Maldonado retweeted
🚨 Obinutuzumab: first FDA-approved therapy for adults with primary membranous nephropathy MAJESTY trial: complete proteinuria remission at week 104: 🔹 Obinutuzumab: 36% 🔹 Tacrolimus: 6% Antigen-based classification is reshaping our understanding
🤖 Made with AI
61
1
163
7,360
Dr.Roberto Collazo-Maldonado retweeted
DNA is proud to sponsor the Texas Indo-American Physicians Society (TIPS) Northeast Chapter 2026 Gala! The evening will feature a special tribute to Dr. Anupkumar Shetty, honoring his contributions to the care of dialysis patients in the DFW area. #TIPS
1
1
66
Dr.Roberto Collazo-Maldonado retweeted
Today, FDA approved the first drug to treat adults with primary membranous nephropathy, a rare kidney disease where the immune system attacks the kidney's filtering units, causing serious complications. This milestone reflects our continued commitment to patients with rare diseases. fda.gov/drugs/news-events-hu…
3
13
3
29
7,768
Dr.Roberto Collazo-Maldonado retweeted
#ASNKidney360 An 18-year-old developed KDIGO stage 3 AKI after minimal naproxen exposure. Pharmacogenetic testing revealed a CYP2C92/2 genotype associated with reduced NSAID metabolism, underscoring a potentially underrecognized contributor to NSAID-associated nephrotoxicity. kidney.pub/KID1431
20
1
47
3,794
Dr.Roberto Collazo-Maldonado retweeted
This Veterans Day, DNA honors all who have served. Thank you for your courage, sacrifice, and dedication to our country. We are grateful today and every day. #VeteransDay #ThankYouVeterans
1
2
29
Dr.Roberto Collazo-Maldonado retweeted
🎆 Fogos de artifício, cantos e a #alegria de um milhão de fiéis! E o #PapaLeãoXIV também canta, enquanto contempla a festa dos jovens que ilumina a noite de Buenos Aires! Foi assim que terminou a #Vigília de Oração realizada nesta terça-feira (10/11), na Argentina
54
668
32
3,634
33,641
Dr.Roberto Collazo-Maldonado retweeted
Hace 98 años nació un hombre que con su música lo cambió todo para siempre, ese hombre se llamaba Ennio Morricone. Eterno.
14
234
15
973
20,065
Dr.Roberto Collazo-Maldonado retweeted
Ironic that the one study showed 4 episodes of blindness in 136,000 patients with placebo or diabetes and 6 in 136,000 and the FDA is now asking for a warning. Is that statistically meaningful to carry a label. It’s not mechanistically clear. What we do know is that there is a 20% reduction in major adverse cardiovascular events in the select trial at four years in a large prospective study using glp1 meds. And that heart disease is the number one cause of mortality worldwide. In the properly selected patients, under physician supervision, they are becoming the standard of care.
The risk of blindness associated with GLP-1 drugs is ~2/100,000 people taking these drugs and properly noted by @FDA, the very rare condition known as NAION wsj.com/health/pharma/u-s-re… by @AlexLJanin
2
5
21
1,421
Dr.Roberto Collazo-Maldonado retweeted
I’m at the @UpToDate Editors meeting today. I’ve been an author/section editor for 20 years. The breaking news is UpToDate Expert AI. Check out UpToDate Expert AI at your institutions. You should have access if you have access to UpToDate. UpToDate Expert AI is unique. It is AI plus the world’s top experts analysis and interpretation rolled into one. It offers AI’s magic and proficiency with the human expert element added. In my experience AI is incredibly helpful but very few of us rely solely on AI to make clinical decisions for a serious illness. Patients still want input from the human expert. Thats what makes UpToDate Expert AI unique. It has both. That helps the treating physician make the best management choice for their patient.
10
29
4
155
20,020
Dr.Roberto Collazo-Maldonado retweeted
💬 Viewpoint by Hanny Al-Samkari, MD, Scott Olitsky, MD, and Michael Auerbach, MD: The new FDA boxed warning for #FerricCarboxymaltose identifies a significant risk of #Hypophosphatemia and related complications, including osteomalacia, fractures, cardiac arrhythmias, and neuromuscular dysfunction. The warning follows a successful FDA Citizen Petition and adds regulatory attention to adverse effects associated with intravenous iron treatment. ja.ma/4etMmRP
4
32
1
95
14,407
Dr.Roberto Collazo-Maldonado retweeted
The FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. FDA fda.gov/safety/medical-produ…
12
70
9
160
33,890
Dr.Roberto Collazo-Maldonado retweeted
La Vía Láctea desde Punta Águila, Cabo Rojo. Luis Cruz Vidal nos comparte esta espectacular captura realizada ayer. En el horizonte todavía se aprecian los últimos destellos del atardecer, creando un hermoso contraste con nuestra galaxia. ¡Gracias, Luis!
1
17
120
1,649
Dr.Roberto Collazo-Maldonado retweeted
From onconephrology to immune-mediated kidney diseases, Meghan E. Sise, MD, MS, has made important contributions across nephrology. Congratulations to this Distinguished Researcher Award recipient. #ASNKidneyNews kidney.pub/KN1811-09
3
31
1,316
Dr.Roberto Collazo-Maldonado retweeted
Correspondence: Hyperaldosteronism Remission after Extended Aldosterone Synthase Inhibition nej.md/4jXjULO #ScientificSessions26 | @AHAScience
4
20
1
51
22,828
Dr.Roberto Collazo-Maldonado retweeted
For the #ScientificSessions26 attendees, from our highly cited collection GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications academic.oup.com/ajh/article… #OpenAccess
1
8
15
874
Dr.Roberto Collazo-Maldonado retweeted
A leader in CKD-mineral and bone disorder research, Sharon M. Moe, MD, FASN, is the recipient of the Barbara T. Murphy Award. Her work has advanced understanding of kidney disease, bone health, and vascular calcification. #ASNKidneyNews kidney.pub/KN1810-26
2
18
1,193